Analyst Conference Summaries

Biotechnology Investor Aids

Ionis Pharmaceuticals

conference date: May 9, 2019 @ 8:30 AM Pacific Time

Ionis Hits Huntington's Milestone [February 1, 2019 @ Seeking Alpha]

Ionis Rising on RNA Therapy Optimism [December 14, 2018 @ Seeking Alpha]

Akcea Undervalued as Commercial Launches Near [April 12, 2018 @ Seeking Alpha]

Ionis is a Buy on RNA Platform Pipeline [March 7, 2018 @ Seeking Alpha]

Q1 2019
May 9, 2019      
Q4 2018
May 4, 2018
August 7, 2018
Nov. 6, 2018
Feb. 27, 2019
Q1 not available
August 8, 2017
Nov. 7, 2017
Feb. 28, 2018

Ionis Pharmaceuticals (IONS) is a biotechnology company specializing in RNA antisense based therapies, including Spinraza. Akcea Therapeutics (AKCA) is majority-owned by Ionis.

Ionis Pharmaceuticals web site

Ionis Pharmaceuticals investor relations



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers